Recent Updates
Recently added Catalysts

Pan-Salmonella vaccine

Phase 1

Salmonella Infections | Monoclonal antibody | Infectious Disease |GSK plc|Last Updated: Jul 28, 2026

Target and mechanism

ModalityMonoclonal antibody

Also known as Pan-Salmonella-with-Alum (Low dose) vaccine, Pan-Salmonella-with-Alum vaccine, Pan-Salmonella-without-Alum (Low dose) vaccine, Pan-Salmonella-without-Alum vaccine

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials1
Total Enrollment196

FDA Designations

No designations recorded

Clinical trial landscape

Pan-Salmonella vaccine · 1 trial · 1 indication

Phase 1 1
NCT07663032A Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GSK Vaccines Institute for Global Health (GVGH) Quadrivalent Pan-Salmonella Vaccine With and Without Alum in Healthy Young AdultsSalmonella Infections
RECRUITING196 Analytics
PHASE1RECRUITING
A Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GSK Vaccines Institute for Global Health (GVGH) Quadrivalent Pan-Salmonella Vaccine With and Without Alum in Healthy Young Adults
Salmonella InfectionsUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of participants with solicited administration site events
From Day 1 to Day 7

Assessed solicited administration site events will be pain, redness and swelling.

Number of participants with solicited systemic events
From Day 1 to Day 7

Assessed solicited systemic events will be fever, headache, myalgia, arthralgia and fatigue.

Number of participants with unsolicited events
From Day 1 to Day 30

An unsolicited adverse event (AE) is an AE that was either not included in the list of solicited AEs, or could. be included in the list of solicited AEs but with an onset outside the specified period of. follow-up for solicited AEs. Unsolicited AEs must have been communicated by participants who have signed informed consent. Unsolicited AEs include serious and non-serious AEs.

Number of participants with serious adverse events (SAEs)
From Day 1 to Day 211

An SAE is defined as any untoward medical occurrence that, at any dose, results in persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening, or results in death.

Number of participants with adverse events (AEs) or SAEs leading to withdrawal from the study or discontinuation of study intervention
From Day 1 to Day 211
Number of participants with changes from baseline or changes from normal values for hematological, renal, and hepatic panels test results
At Day 8

Secondary Endpoints

Number of participants with serious adverse events (SAEs)
From Day 211 to Day 361
Number of participants with AEs/SAEs leading to withdrawal from the study or discontinuation of study intervention
From Day 211 to Day 361
Geometric mean concentration (GMC) of anti-serotype specific immunoglobulin G (IgG) antibody
Pre-intervention at Day 1, Day 61 and Day 181
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelSEQUENTIAL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
Pan-Salmonella with Alum (Low dose) GroupEXPERIMENTALParticipants will receive the low dose level of the candidate Pan-Salmonella-with-aluminium-hydroxide (Alum) vaccine at Days 1, 61 and 181.
Pan-Salmonella with Alum (Full dose) GroupEXPERIMENTALParticipants will receive the full dose level of the candidate Pan-Salmonella-with-Alum vaccine at Days 1, 61 and 181.
Pan-Salmonella without Alum (Low dose) GroupEXPERIMENTALParticipants will receive the low dose level of the candidate Pan-Salmonella-without-Alum vaccine at Days 1, 61 and 181.
Pan-Salmonella without Alum (Full dose) GroupEXPERIMENTALParticipants will receive the full dose level of the candidate Pan-Salmonella-without-Alum vaccine at Days 1, 61 and 181.
Control GroupPLACEBO_COMPARATORParticipants will receive placebo at Days 1 and 181, and Typhoid Vi conjugate vaccine at Day 61.

Interventions

NameTypeDescription
Pan-Salmonella-with-Alum (Low dose) vaccineBIOLOGICALParticipants receive low dose of the Pan-Salmonella-with-Alum.
Pan-Salmonella-with-Alum (Full dose) vaccineBIOLOGICALParticipants receive full dose of the Pan-Salmonella-with-Alum.
Pan-Salmonella-without-Alum (Low dose) vaccineBIOLOGICALParticipants receive low dose of the Pan-Salmonella-without-Alum.
Pan-Salmonella-without-Alum (Full dose) vaccineBIOLOGICALParticipants receive full dose of the Pan-Salmonella-without-Alum.
Typhoid Vi conjugate vaccineBIOLOGICALParticipants receive Typhoid Vi conjugate vaccine as control
PlaceboOTHERParticipants receive Placebo (saline solution) as control.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 45 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Participants who, in the opinion of the Investigator, can and will comply with the requirements of the protocol (e.g., completion of the Diary cards, return for follow-up visits). 2. Written informed consent obtained from the participant prior to performance of any study spec...

Countries:South Africa
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWJul 28, 2026NCT07663032Status: NOT_YET_RECRUITING → RECRUITING
LOWJul 28, 2026NCT07663032Status: NOT_YET_RECRUITING → RECRUITING
LOWJun 23, 2026NCT07663032NEW_TRIAL: changed
LOWJun 23, 2026NCT07663032NEW_TRIAL: changed